Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01984320
Other study ID # 92013
Secondary ID
Status Completed
Phase N/A
First received October 31, 2013
Last updated August 11, 2017
Start date October 2013
Est. completion date July 2015

Study information

Verified date August 2017
Source Cairo University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The effectiveness of cabergoline to prevent moderate-severe OHSS to coasting.


Description:

To randomly compare three study groups under a high risk of developing OHSS to one of three arms of management, either coasting for 1 to 3 days or receiving cabergoline for 8 days or coasting for 1 day plus receiving cabergoline for 8 days in ICSI patients following the long luteal GnRH agonist protocol.


Recruitment information / eligibility

Status Completed
Enrollment 300
Est. completion date July 2015
Est. primary completion date July 2015
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 35 Years
Eligibility Inclusion Criteria:

1. Age <or= 35, BMI <or= 30

2. Long protocol GnRH agonist cycles

3. Estradiol level on day of HCG >or= 3500 pg/ml

4. Retrieving more than 15 oocytes

Exclusion Criteria:

1. Male factor

2. Uterine factor

Study Design


Related Conditions & MeSH terms

  • OHSS
  • Ovarian Hyperstimulation Syndrome

Intervention

Procedure:
ICSI
Long luteal GnRH agonist protocol: patients will receive GnRH agonist from day 21 of the previous cycle of stimulation and then on day 3 of the stimulation cycle they will start hMG injections with 225 IU/day. Folliculometry will start on day 6 stimulation by vaginal ultrasound. Estradiol levels will be measured on day 8, 10 and 12 of stimulation if appropriate. According to ultrasound and estradiol level patients will be randomized to either one of the study arms. When ready final triggering will be done by human chorionic gonadotropin (10000 IU) and oocyte collection is done at 36 hour from triggering. Embryo transfer is then done 3 days afterwards with ultrasound guidance.

Locations

Country Name City State
Egypt IVF centre, Obstetrics and Gynaecology Department, Cairo University Hospitals (Kasr EL Aini) Cairo

Sponsors (1)

Lead Sponsor Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

References & Publications (1)

Esinler I, Bozdag G, Karakocsokmensuer L. Preventing ovarian hyperstimulation syndrome: cabergoline versus coasting. Arch Gynecol Obstet. 2013 Nov;288(5):1159-63. doi: 10.1007/s00404-013-2875-z. Epub 2013 May 16. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Number of Metaphase II (MII) oocytes Number of MII oocytes collected on the day of oocyte collection 1 day
Other Fertilization rate Number of embryos that show signs of fertilization in each patient 2 days
Other Number of embryos Number of embryos assessed for embryo transfer in each patient 3 to 5 days
Other Implantation rate the ratio of the number of gestational sacs to the number of embryos transferred 5 weeks
Other Chemical pregnancy rate The patients who have a positive quantitative Beta human chorionic gonadotrophin (BHCG) and do not continue their pregnancy with a drop in the result and start of menstruation 14 days
Other Clinical pregnancy rate patients who show an intra-uterine gestational sac with positive fetal pulsations on ultrasound 14 days after their pregnancy test 28 days
Other Early miscarriage rate pregnancy loss in the first 12 weeks of gestation 12 weeks
Other Ongoing pregnancy rate pregnancies going beyond 12 weeks of gestation 12 weeks
Other Live birth rate live births occuring 40 weeks
Primary Rate and degree of OHSS (composite outcome) Symptoms of nausea, vomiting, shortness of breath, abdominal pain,abdominal distension. Ovarian size and fluid in douglas pouch by ultrasound. Haematocrit, total leucocytic count, creatinine and Estradiol level as biochemical markers. Early OHSS first 9 days after ovum pickup and late is after 9 days till 14 days (time of pregnancy test) 14 days
Secondary Number of oocytes Number of oocytes collected on the day of oocyte collection 1 day
See also
  Status Clinical Trial Phase
Completed NCT02875587 - Cabergoline Versus Calcium Gluconate Infusion in the Prevention of Ovarian Hyperstimulation Syndrome Phase 2
Recruiting NCT02358421 - Prediction of High Ovarian Response After Assisted Reproductive Techniques N/A
Completed NCT01709942 - Use of Degarelix in Controlled Ovarian Hyperstimulation (COH) Protocol for Women With PoliCystic Ovarian Syndrome (PCOS) Phase 3
Completed NCT02148393 - Implantation Enhancement by Elective Cryopreservation of All Viable Embryos N/A
Recruiting NCT02461875 - Cabergoline Versus GnRH Antagonist Rescue and Cabergoline in the Prevention of Ovarian Hyperstimulation Syndrome Phase 2